Whalesbook
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
Leading Pharmaceutical CompanyThe company isIndia’s 2nd-largest listed pharma company based on revenue & the largest generics company in the US. It is ranked among the top 10 generic companies in 8 European countries.[1]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1806.70 | 37.55 | 433487.85 | 0.89 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.57 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6455.00 | 68.96 | 171359.97 | 0.46 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.12 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 3720.90 | 58.12 | 125926.51 | 0.86 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 14.90 | 13.26 | 0.33 |
| 4. | Cipla | 1508.00 | 22.39 | 121811.90 | 0.86 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.70 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1280.70 | 18.52 | 106889.94 | 0.62 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.97 | 12.95 | 0.16 |
| 6. | Lupin | 2080.10 | 21.97 | 95011.10 | 0.58 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 4.84 | 12.41 | 0.32 |
| 7. | Zydus Lifesci. | 934.95 | 18.71 | 94077.85 | 1.18 | 1238.60 | 40.92 | 6123.20 | 16.92 | 24.31 | 24493.90 | 31.10 | 5029.35 | 1283.60 | 3.72 | 14.64 | 0.38 |
| 8. | Aurobindo Pharma | 1208.90 | 34.75 | 70213.11 | 0.33 | 581.37 | 8.16 | 2789.72 | -1.23 | 10.81 | 11286.51 | 25.08 | 2020.72 | 581.37 | 3.27 | 6.61 | 0.21 |
| – | Median: 148 Co. | 411.9 | 31.93 | 1668.03 | 0.12 | 12.57 | 12.32 | 152.64 | 10.54 | 14.85 | 582.87 | 15.93 | 44.55 | 13.49 | 3.21 | 8.39 | 0.22 |
Standalone figures in ₹ crores
| Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 1,948 | 2,361 | 2,406 | 2,391 | 2,669 | 2,692 | 2,894 | 2,460 | 2,825 | 2,917 | 2,732 | 2,848 | 2,790 |
Expenses | 1,680 | 1,917 | 1,830 | 1,968 | 2,124 | 2,210 | 2,119 | 1,961 | 2,104 | 2,203 | 2,135 | 2,052 | 2,065 |
Operating Profit | 268 | 444 | 576 | 422 | 545 | 482 | 775 | 499 | 721 | 713 | 597 | 796 | 725 |
Other Income | 36 | 54 | 326 | 113 | 103 | 331 | 123 | 65 | 123 | 54 | 114 | 84 | 160 |
Profit before tax | 231 | 413 | 804 | 444 | 546 | 687 | 780 | 446 | 724 | 633 | 556 | 750 | 755 |
Tax % | 29% | 28% | 20% | 24% | 24% | 9% | 26% | 26% | 26% | 25% | 27% | 25% | 23% |
Net Profit | 165 | 299 | 645 | 336 | 416 | 624 | 579 | 329 | 538 | 472 | 408 | 559 | 581 |
EPS in Rs | 2.81 | 5.10 | 11.01 | 5.74 | 7.10 | 10.65 | 9.88 | 5.62 | 9.25 | 8.13 | 7.03 | 9.63 | 10.01 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 7,108 | 8,069 | 9,158 | 9,607 | 10,270 | 12,258 | 13,371 | 15,824 | 11,287 | 12,792 | 10,646 | 10,933 | 11,287 |
Expenses | 5,187 | 5,816 | 6,705 | 7,215 | 7,600 | 9,838 | 10,670 | 11,704 | 9,783 | 11,061 | 8,422 | 8,376 | 8,456 |
Operating Profit | 1,922 | 2,253 | 2,453 | 2,392 | 2,670 | 2,420 | 2,700 | 4,120 | 1,504 | 1,731 | 2,224 | 2,558 | 2,831 |
Other Income | 73 | 65 | 187 | 118 | 81 | 189 | 386 | 590 | 565 | 434 | 670 | 328 | 412 |
Interest | 289 | 132 | 229 | 45 | 53 | 231 | 243 | 29 | 17 | 115 | 183 | 230 | 245 |
Depreciation | 186 | 245 | 263 | 286 | 355 | 413 | 473 | 488 | 415 | 435 | 255 | 297 | 304 |
Profit before tax | 1,519 | 1,940 | 2,148 | 2,179 | 2,343 | 1,965 | 2,370 | 4,193 | 1,637 | 1,614 | 2,457 | 2,358 | 2,694 |
Net Profit | 1,172 | 1,516 | 1,627 | 1,707 | 1,813 | 1,530 | 1,877 | 3,113 | 1,455 | 1,230 | 1,954 | 1,747 | 2,021 |
EPS in Rs | 20.11 | 25.96 | 27.80 | 29.13 | 30.94 | 26.11 | 32.03 | 53.13 | 24.83 | 21.00 | 33.35 | 30.08 | 34.80 |
Dividend Payout % | 7% | 9% | 9% | 9% | 8% | 10% | 9% | 8% | 36% | 36% | 13% | 0% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 29 | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
Reserves | 3,983 | 5,330 | 6,807 | 8,378 | 9,924 | 11,292 | 12,994 | 15,866 | 17,059 | 17,856 | 19,664 | 20,476 | 21,383 |
Borrowings | 2,925 | 3,285 | 4,165 | 3,054 | 3,719 | 4,520 | 3,741 | 4,028 | 1,895 | 4,203 | 2,861 | 4,647 | 4,429 |
Other Liabilities | 1,638 | 1,582 | 1,534 | 1,533 | 2,092 | 2,270 | 2,770 | 3,237 | 2,589 | 2,816 | 2,570 | 2,332 | 2,178 |
Total Liabilities | 8,576 | 10,226 | 12,566 | 13,023 | 15,794 | 18,141 | 19,564 | 23,189 | 21,601 | 24,934 | 25,154 | 27,513 | 28,047 |
Fixed Assets | 1,938 | 2,190 | 2,568 | 3,212 | 3,393 | 4,150 | 4,418 | 4,472 | 3,586 | 3,688 | 2,419 | 2,337 | 2,433 |
Gross Block | 3,009 | 3,508 | 2,831 | 3,758 | 4,292 | 5,446 | 6,181 | 6,820 | 5,725 | 6,215 | 4,043 | 4,231 | – |
Accumulated Depreciation | 1,071 | 1,318 | 263 | 547 | 899 | 1,296 | 1,763 | 2,348 | 2,139 | 2,527 | 1,624 | 1,894 | – |
CWIP | 204 | 227 | 742 | 907 | 1,144 | 789 | 815 | 735 | 225 | 239 | 133 | 88 | 209 |
Investments | 873 | 1,013 | 1,183 | 1,682 | 1,968 | 2,339 | 2,527 | 5,010 | 6,584 | 8,222 | 13,393 | 15,210 | 16,437 |
Other Assets | 5,561 | 6,796 | 8,072 | 7,222 | 9,289 | 10,863 | 11,804 | 12,972 | 11,206 | 12,785 | 9,209 | 9,879 | 8,968 |
Total Assets | 8,576 | 10,226 | 12,566 | 13,023 | 15,794 | 18,141 | 19,564 | 23,189 | 21,601 | 24,934 | 25,154 | 27,513 | 28,047 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 328 | 590 | 1,185 | 2,457 | 922 | 530 | 2,201 | 2,994 | 3,727 | 1,821 | 1,715 | 1,646 |
Cash from Investing Activity | -401 | -624 | -1,390 | -1,542 | -991 | -1,301 | -948 | -2,650 | -1,615 | -3,459 | -152 | -2,050 |
Cash from Financing Activity | -31 | 35 | 515 | -1,329 | 440 | 599 | -1,255 | -28 | -2,448 | 1,719 | -1,837 | 616 |
Net Cash Flow | -105 | 1 | 310 | -414 | 371 | -171 | -1 | 316 | -335 | 81 | -274 | 212 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 153 | 168 | 175 | 143 | 159 | 156 | 158 | 137 | 128 | 130 | 129 | 140 |
Inventory Days | 179 | 207 | 207 | 191 | 273 | 235 | 242 | 244 | 210 | 219 | 148 | 154 |
Days Payable | 130 | 111 | 109 | 96 | 130 | 109 | 107 | 104 | 104 | 117 | 112 | 116 |
Cash Conversion Cycle | 202 | 264 | 273 | 239 | 301 | 282 | 293 | 277 | 234 | 232 | 166 | 177 |
Working Capital Days | 90 | 108 | 84 | 92 | 106 | 107 | 132 | 118 | 181 | 83 | 65 | 32 |
ROCE % | 29% | 27% | 24% | 20% | 19% | 15% | 16% | 23% | 9% | 8% | 12% | 11% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Aug 2025
Jun 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
Jun 2023
Feb 2023
Feb 2023
Feb 2023
Nov 2022
Aug 2022
Jun 2022
Feb 2022
Nov 2021
Sep 2021
Aug 2021
Jun 2021
Feb 2021
Nov 2020
Aug 2020
Jun 2020
Feb 2020
Feb 2020
Jan 2020
Nov 2019
Nov 2019
Aug 2019
Aug 2019
Aug 2019
Jun 2019
May 2019
Mar 2019
Feb 2019
Feb 2019
Jan 2019
Nov 2018
Nov 2018
Sep 2018
Sep 2018
Aug 2018
Aug 2018
Jun 2018
May 2018
Mar 2018
Feb 2018
Feb 2018
Feb 2018
Jan 2018
Nov 2017
Nov 2017
Sep 2017
Aug 2017
Aug 2017
Jun 2017
Jun 2017
Jun 2017
May 2017
Mar 2017
Feb 2017
Feb 2017
Nov 2016
Nov 2016
Sep 2016
Sep 2016
Aug 2016
Aug 2016
Jun 2016
Feb 2016
